2026-09-18 Otsuka Holdings Co.,Ltd. “FACEDUO has launched new content titled "Understanding a New Perspective on Dementia."”
2026-09-18 Otsuka Holdings Co.,Ltd. “FACEDUO has launched new content titled "Understanding a New P … 続きを読む
JP3188220002
2026-09-16 Otsuka Holdings Co.,Ltd. “EN Otsuka Pharmaceutical has obtained manufacturing and marketing approval for its enteral nutrition formula, "Innofeed® Enteral Solution."”
2026-09-16 Otsuka Holdings Co.,Ltd. “EN Otsuka Pharmaceutical has obtained manufacturing and marketing a … 続きを読む
2026-09-14 Otsuka Holdings Co.,Ltd. “In the Phase III REZILIENT3 trial for first-line treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations, the combination of diparereltinib and chemotherapy extended the median progression-free survival by 6 months.”
2026-09-14 Otsuka Holdings Co.,Ltd. “In the Phase III REZILIENT3 trial for first-line treatment of non-s … 続きを読む
2026-08-28 Otsuka Holdings Co.,Ltd. “Otsuka Holdings and Sojitz have signed a virtual PPA with a special purpose company they established – promoting carbon neutrality initiatives through the expansion of "self-generated renewable energy."”
2026-08-28 Otsuka Holdings Co.,Ltd. “Otsuka Holdings and Sojitz have signed a virtual PPA with a special … 続きを読む
2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer (Link to Taiho Oncology's English page).”
2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial … 続きを読む
2026-08-20 Otsuka Holdings Co.,Ltd. “"SOYJOY Matcha & Yuzu" New Release: A rich and flavorful matcha is complemented by the vibrant taste of yuzu.”
2026-08-20 Otsuka Holdings Co.,Ltd. “"SOYJOY Matcha & Yuzu" New Release: A rich and flavor … 続きを読む
2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer (Link to Taiho Oncology's English page).”
2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial … 続きを読む
2026-08-20 Otsuka Holdings Co.,Ltd. “"SOYJOY Matcha & Yuzu" New Release: A rich and flavorful matcha is complemented by the vibrant taste of yuzu.”
2026-08-20 Otsuka Holdings Co.,Ltd. “"SOYJOY Matcha & Yuzu" New Release: A rich and flavor … 続きを読む
2026-08-17 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory has obtained manufacturing and marketing approval for the V₂-receptor antagonist tolvaptan OD tablets 30mg "Otsuka".”
2026-08-17 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory has obtained manufacturing and market … 続きを読む
2026-08-13 Otsuka Holdings Co.,Ltd. “In an interim analysis of the Phase III REZILIENT3 trial in the group receiving diparereltinib in combination with chemotherapy for first-line treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations, the primary endpoint of progression-free survival was achieved.”
2026-08-13 Otsuka Holdings Co.,Ltd. “In an interim analysis of the Phase III REZILIENT3 trial in the gro … 続きを読む